PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Vice President at Johnson and Johnson to Speak at Modern Drug Summit October 19-21 in San Diego - William R. Strohl, Vice President of Biologics Research at Johnson & Johnson, will give a plenary keynote presentation on “The Future of Antibodies and Antibody-Like Protein Therapeutics” at the 7th Modern Drug Discovery and Development Summit
Vice President at Johnson and Johnson to Speak at Modern Drug Summit October 19-21 in San Diego

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2011/08/30 - William R. Strohl, Vice President of Biologics Research at Johnson & Johnson, will give a plenary keynote presentation on “The Future of Antibodies and Antibody-Like Protein Therapeutics” at the 7th Modern Drug Discovery and Development Summit.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

William R. Strohl, Vice President of Biologics Research at Johnson & Johnson, will give a plenary keynote presentation on “The Future of Antibodies and Antibody-Like Protein Therapeutics” at the 7th Modern Drug Discovery and Development Summit to be held in San Diego, CA on October 19-21, 2011 by GTC.

Since 2001, monoclonal antibodies (MAbs) and Fc fusion proteins (FcFPs) have gone from being specialty drugs to major growth drivers in the pharmaceutical industry. In 2001, the market for MAbs and FcFPs was ~$3B, whereas today it is $51B with seven MAbs and FcFPs >$3B annually. With 36 MAbs and FcFPs currently marketed and another 35 in Phase III clinical trials, the market is expected to grow to $75-90B by 2015, not even accounting for the potential expansion into new markets. The future for MAbs and FcFPs, however, faces many challenges including: (i) five or more companies competing on each of the top 16 targets; (ii) the low rate of identification and validation of novel targets; (iii) increased pricing pressures from governments and third-party payors; (iv) increased competition from follow-on biologics; and (iv) the rising costs for discovery and development. Moreover, the technologies to make human MAbs and FcFPs are becoming commoditized, so the barriers to entry are decreasing, which should increase competition further. Many companies are responding to these challenges by increasing efforts to develop Fc engineered MAbs, bispecific MAbs, tissue-targeted MAbs, and single-drug MAb combinations. How companies respond to these challenges in the next 3-5 years will spell out the future up to 2025.

William R. Strohl moved to Merck in 1997 to head up Natural Products Microbiology, which he did for 4 years before being asked to start a new department in the field of recombinant monoclonal antibodies. From 2001 to 2008, Dr. Strohl was a leader in Merck’s efforts to develop therapeutic monoclonal antibodies, as well as in-licensing of therapeutic targets and technologies associated with monoclonal antibodies. As part of this effort, Dr. Strohl was the scientific leader in the acquisition and integration of Abmaxis and GlycoFi into the Merck Biologics organization. In April, 2008, Dr. Strohl was named leader of Antibody Drug Discovery at Centocor (J&J). Concomitant with the evolution of Biologics at Johnson & Johnson to serve additional therapeutic areas beyond Immunology and Oncology, Dr. Strohl was recently named as VP and Head, Biologics Research, in the J&J Biotechnology Center of Excellence. Dr. Strohl has over 100 publications and several patents, has edited two books, and is currently writing a book entitled “Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharma Industry” to be published in spring, 2012.

The 7th Modern Drug Discovery and Development Summit will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. Over 125 leading industrial and academic experts will present at this three-day summit and is comprised of a half day plenary keynote session and 4 full conferences. The M3D Summit includes the following conferences:

5th Biomarker Discovery and Development
5th Drug Design and Medicinal Chemistry
5th Advances in Stem Cell Discovery and Development
4th Protein Discovery & Therapeutics

For more information, please visit gtcbio.com/.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Vice President at Johnson and Johnson to Speak at Modern Drug Summit October 19-21 in San Diego

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit MagLar, Inc.

Visit  Explorers Vacation Club





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)